Nicolaas Schaap Selected Research

16-iodo-3-methylhexadecanoic acid (MIHA)

1/2018	Increased Coexpression of PD-1, TIGIT, and KLRG-1 on Tumor-Reactive CD8+ T Cells During Relapse after Allogeneic Stem Cell Transplantation.
5/2015	Efficient nontoxic delivery of PD-L1 and PD-L2 siRNA into dendritic cell vaccines using the cationic lipid SAINT-18.
11/2014	Inhibition of Akt signaling promotes the generation of superior tumor-reactive T cells for adoptive immunotherapy.
7/2012	B and T lymphocyte attenuator mediates inhibition of tumor-reactive CD8+ T cells in patients after allogeneic stem cell transplantation.
8/2011	PD-1/PD-L1 interactions contribute to functional T-cell impairment in patients who relapse with cancer after allogeneic stem cell transplantation.
11/2010	siRNA silencing of PD-L1 and PD-L2 on dendritic cells augments expansion and function of minor histocompatibility antigen-specific CD8+ T cells.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Nicolaas Schaap Research Topics

Disease

22	Neoplasms (Cancer) 01/2021 - 02/2010
14	Multiple Myeloma 06/2022 - 03/2010
11	Leukemia 01/2022 - 11/2010
9	Primary Myelofibrosis (Myelosclerosis) 01/2022 - 07/2017
8	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 10/2021 - 03/2015
6	Hematologic Neoplasms (Hematological Malignancy) 01/2018 - 01/2011
4	Graft vs Host Disease (Graft-Versus-Host Disease) 01/2019 - 02/2013
3	Myeloid Leukemia (Leukemia, Myelocytic) 01/2013 - 08/2011
2	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 01/2020 - 10/2017
2	Lymphoma (Lymphomas) 01/2018 - 10/2017
2	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 01/2018 - 03/2015
1	Splenomegaly 06/2020
1	Cytopenia 06/2020
1	Disease Progression 01/2020
1	Blast Crisis (Blast Phase) 10/2019
1	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 10/2019
1	Thrombocytopenia (Thrombopenia) 10/2019
1	Carcinoma (Carcinomatosis) 02/2019
1	Ovarian Neoplasms (Ovarian Cancer) 02/2019
1	Chromosome Aberrations (Chromosome Abnormalities) 01/2018
1	Wernicke Encephalopathy (Wernicke's Encephalopathy) 07/2017
1	Residual Neoplasm 06/2016
1	Infections 05/2014
1	Virus Diseases (Viral Diseases) 02/2013
1	B-Cell Lymphoma (Lymphoma, B Cell) 07/2012

Drug/Important Bio-Agent (IBA)

8	Minor Histocompatibility AntigensIBA 01/2018 - 11/2010
7	ruxolitinibIBA 01/2022 - 07/2017
6	fedratinibIBA 01/2022 - 07/2017
6	16-iodo-3-methylhexadecanoic acid (MIHA)IBA 01/2018 - 11/2010
3	Janus Kinase InhibitorsIBA 01/2022 - 06/2020
3	AntigensIBA 10/2016 - 02/2013
2	VaccinesIBA 01/2017 - 11/2010
2	Messenger RNA (mRNA)IBA 08/2013 - 02/2013
2	Small Interfering RNA (siRNA)IBA 02/2013 - 11/2010
2	LigandsIBA 07/2012 - 08/2011
1	Immunoglobulin D (IgD)IBA 10/2021
1	Core Binding Factor Alpha 2 SubunitIBA 10/2021
1	Immunoglobulin M (IgM)IBA 10/2021
1	Janus Kinase 2IBA 05/2021
1	11- (2- pyrrolidin- 1- ylethoxy)- 14,19- dioxa- 5,7,26- triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa- 1(25),2(26),3,5,8,10,12(27),16,21,23- decaeneIBA 06/2020
1	Pharmaceutical PreparationsIBA 06/2020
1	N- (cyanomethyl)- 4- (2- ((4- (4- morpholinyl)phenyl)amino)- 4- pyrimidinyl)benzamideIBA 06/2020
1	fludarabineIBA 01/2020
1	Busulfan (Busulfex)FDA Link 01/2020
1	plerixafor FDA Link 01/2020
1	ibrutinibIBA 01/2020
1	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 01/2020
1	Tyrosine Kinase InhibitorsIBA 10/2019
1	Sorafenib (BAY 43-9006)FDA Link 03/2019
1	Blocking AntibodiesIBA 01/2018
1	Melphalan (Alkeran)FDA LinkGeneric 01/2018
1	Phosphotransferases (Kinase)IBA 10/2017
1	InterferonsIBA 12/2015
1	B-Cell Maturation AntigenIBA 08/2013
1	SurvivinIBA 08/2013
1	DNA (Deoxyribonucleic Acid)IBA 02/2013
1	Interleukin-15 (Interleukin 15)IBA 01/2013
1	AntibodiesIBA 08/2011
1	CytokinesIBA 11/2010
1	HLA Antigens (Human Leukocyte Antigens)IBA 11/2010

Therapy/Procedure

29	Stem Cell Transplantation 06/2022 - 03/2010
10	Transplantation 01/2020 - 03/2015
8	Immunotherapy 06/2022 - 02/2010
7	Therapeutics 12/2021 - 11/2014
4	Drug Therapy (Chemotherapy) 10/2021 - 01/2013
3	Hematopoietic Stem Cell Transplantation 12/2021 - 01/2018
2	Cell Transplantation 10/2021 - 10/2017
2	Autologous Transplantation 01/2018 - 01/2018
1	Hematopoietic Stem Cell Mobilization 01/2020
1	Salvage Therapy 01/2020
1	Duration of Therapy 10/2019
1	Parenteral Infusions 02/2019
1	Kidney Transplantation 01/2019
1	Ligation 01/2018
1	Homologous Transplantation 12/2015